Get the Stockscreener App
30.15
1.12%
-0.34
After Hours:
30.15
Harmony Biosciences Holdings Inc stock is traded at $30.15, with a volume of 412.55K.
It is down -1.12% in the last 24 hours and down -5.69% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$30.49
Open:
$30.51
24h Volume:
412.55K
Relative Volume:
0.43
Market Cap:
$1.75B
Revenue:
$868.45M
Net Income/Loss:
$158.69M
P/E Ratio:
11.13
EPS:
2.7087
Net Cash Flow:
$328.64M
1W Performance:
+0.20%
1M Performance:
-5.69%
6M Performance:
-12.12%
1Y Performance:
-11.66%
1-Day Range:
$29.96
$30.81
1-Week Range:
$29.67
$31.54
52-Week Range:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
30.15 | 1.77B | 868.45M | 158.69M | 328.64M | 2.7087 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-23-26 | Downgrade | Truist | Buy → Hold |
| Feb-11-26 | Resumed | UBS | Neutral |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Trading the Move, Not the Narrative: (HRMY) Edition - Stock Traders Daily
HRMY SEC FilingsHarmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright reiterates Harmony Biosciences stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Revenue Rises as WAKIX Franchise Expands - MyChesCo
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities - Quantisnow
A beaten-down biotech just lost a meaningful backer — should you care? - sharewise.com
A beaten-down biotech just lost a meaningful backer — should you care? - The Motley Fool
Harmony Biosciences Holdings, Inc.Common Stock (NQ: HRMY - FinancialContent
Harmony Biosciences (HRMY) director Germano Geno J files initial insider Form 3 - Stock Titan
Harmony Biosciences (HRMY) director receives 21,872-share stock option grant - Stock Titan
Harmony Biosciences director granted 21,872 options | HRMY Insider Trading - Stock Titan
Director Graf R. Mark receives 21,872 HRMY stock options in new equity grant - Stock Titan
Harmony Biosciences (HRMY) director awarded 21,872 stock options at $30.76 strike price - Stock Titan
Director Gary Sender receives 21,872 stock options at Harmony Biosciences (HRMY) - Stock Titan
Harmony Biosciences (HRMY) CMO exercises RSUs and covers tax withholding - Stock Titan
Harmony Biosciences (HRMY) CFO granted 164,309 stock options at $29.29 strike - Stock Titan
Harmony Biosciences (HRMY) CFO files initial Form 3 insider report - Stock Titan
Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY) - simplywall.st
Number of shareholders of Harmony Biosciences Holdings, Inc. – NASDAQ:HRMY - TradingView
Harmony Biosciences Shareholders Approve Governance Measures at Meeting - TipRanks
Harmony Biosciences (HRMY) shareholders elect directors, ratify auditor and back pay - Stock Titan
Harmony Biosciences Holdings Inc Annual Shareholders Meeting Transcript - GuruFocus
Harmony Biosciences’ Four Key Pillars to Drive Value Creation - Sleep Review
Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality - simplywall.st
Harmony Biosciences Holdings, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HRMY) 2026-05-13 - Seeking Alpha
(HRMY) Volatility Zones as Tactical Triggers - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Liquidia Technologies (LQDA) - The Globe and Mail
Harmony Biosciences Holdings (HRMY) Announces Financial Results for Q1 2026 - Insider Monkey
H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Harmony Biosciences Holdings, Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next - simplywall.st
Earnings Miss: Harmony Biosciences Holdings, Inc. Missed EPS By 21% And Analysts Are Revising Their Forecasts - Yahoo Finance
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised - TradingView
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Vanguard Group Inc. - MarketBeat
10 Best Healthcare Stocks to Buy for the Long Term - Insider Monkey
Harmony Biosciences Holdings, Inc. (HRMY) Q1 earnings and revenues miss estimates - MSN
Harmony Biosciences Holdings HRMY Margin Compression Challenges Bullish Valuation Narratives - Sahm
Harmony Biosciences Holdings (HRMY) Valuation After Q1 2026 Earnings Miss And Profitability Concerns - Yahoo Finance
Harmony outlines $1B-$1.04B 2026 net revenue plan while targeting pitolisant GR PDUFA in Q1 2027 - MSN
Wall Street analysts think Harmony Biosciences (HRMY) could surge 34.81%: Read this before placing a bet - MSN
Is Harmony Biosciences Holdings, Inc. (HRMY) One of The Best Small Cap Value Stocks to Buy? - Insider Monkey
[144] Harmony Biosciences Holdings, Inc. SEC Filing - Stock Titan
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $45 - Moomoo
Should Harmony Biosciences’ Softer Q1 2026 Earnings and Upbeat Forecasts Require Action From HRMY Investors? - Yahoo Finance
Harmony Biosciences Q1 Earnings Call Highlights - Yahoo Finance
Harmony Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
5 Best Small-Cap Value Stocks to Buy - Insider Monkey
HRMY: Q1 revenue up 17% to $215.4M; strong WAKIX growth and pipeline advance support $1B+ guidance - TradingView
Why Is Harmony Biosciences Holdings (HRMY) Dropping 8.4%? - AlphaStreet
HRMY: Q1 revenue rose 17% to $215.4M, with strong WAKIX growth and guidance reaffirmed - TradingView
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):